Q3'26 Quarterly Results November 20, 2025 This presentation and associated commentary contain forward-looking statements regarding Veeva's expected future performance and, in particular, includes guidance, provided as of November 20, 2025, about Veeva's expected future financial results. Estimating guidance accurately for future periods is difficult. It involves assumptions and internal estimates that may prove to be incorrect and is based on plans that may change. Hence, there is a significant risk that ac ...

Corporate Overview and Q2FY26 Financial Results November 20, 2025 Forward Looking Statements; Use of Non-GAAP Measures This presentation and the accompanying oral presentation contain forward-looking statements that involve substantial risks and uncertainties, which include, but are not limited to, statements regarding our expected financial results for the fiscal quarter ending January 31, 2026 and fiscal year ending April 30, 2026, our strategic areas of focus, expectations and plans regarding our future ...

Fact Sheet November 20, 2025 Financial summary | Financial Summary | | | FY'24 | | | | | FY'25 | | | FY'26 | | Guidance[C] | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | ($ millions, except per share data) | Q1 | Q2 | Q3 | Q4 | FY | Q1 | Q2 | Q3 | Q4 | FY | Q1 | Q2 FY'26 | | FY'26 | | Global Business Solutions | $2,344 | $2,245 | $2,387 | $2,557 | $9,533 | $2,544 | $2,671 | $2,849 | $3,013 | $11,077 | $2,991 | | | $12,633 - $12,742 | | % change YoY | 18% | ...

Speaker1 All right, good afternoon. Our next presenting company is Smith-Midland, trades on the NASDAQ under the ticker SMID. Third-generation run family business that is involved in the precast concrete sector. It has some very other very interesting things going on. They are a Three Part Advisors client, so if any of you'd like to speak to them afterwards or set up a call next week after Thanksgiving, happy to take care of that for you. Here today to start the presentation is the CEO, Ashley Smith, and wi ...

MVB Financial Corp (NasdaqCM:MVBF) FY Conference November 20, 2025 03:00 PM ET Speaker0Thank you for attending the three-part advisors' ideas conference on CME marketing. The next step is MVB Financial Corp. Carried on the NASDAQ, took our MVB guest. And today we have Larry Mazza with his president, CEO, and Michael Sarnas, and he's a CFO. I'll let Larry take it away.Speaker2Thank you, Sandy.Speaker1Good afternoon. I'm Larry Mazza, as she said, from MVB. I'm CEO. Quick background on myself: started out at K ...

Summary of TriSalus Life Sciences Conference Call Company Overview - **Company**: TriSalus Life Sciences (NasdaqGM: TLSI) - **Industry**: Oncology medical technology - **Technology**: Pressure-enabled drug delivery system designed to enhance drug delivery to tumors while minimizing exposure to normal tissues [2][6] Core Points and Arguments - **Market Opportunity**: The microcatheter market is valued at $2.5 billion, with TriSalus focusing primarily on liver applications, holding less than 10% market share, indicating significant growth potential [2][8] - **Growth Rate**: The company has experienced a growth rate of 50% annually with an 85% gross margin [2][8] - **Clinical Benefits**: The technology has shown to increase drug delivery to tumors by 40%-500%, leading to improved patient outcomes and reduced hospital readmission rates by 50% [5][7] - **Reimbursement**: TriSalus has secured favorable reimbursement codes from CMS, which are permanent and unique to their technology, enhancing economic viability for hospitals [7][8][31] - **Device Variants**: The company offers multiple device configurations (TriNav, TriNav Large, TriNav Flex) tailored to different patient anatomies [5][8] Additional Applications - **Uterine Fibroids**: The technology has been adapted for treating uterine fibroids, providing a less invasive option compared to surgery [9][10] - **Multinodular Goiter**: TriSalus is exploring applications for treating thyroid nodules, which can be accessed via a less invasive route [11][12] - **Pancreatic Cancer**: The company is developing a device for pancreatic cancer treatment, utilizing venous anatomy for drug delivery [13][14] - **Genicular Artery Embolization**: A new application for osteoarthritis treatment is being explored, with promising initial results [15][16] Financial Performance - **Q3 Earnings**: Reported earnings of $11.6 million, with expectations for a strong Q4 due to year-end spending [16][18] - **Operational Expenses**: Targeting $14 million in GAAP operational expenses, with a focus on maintaining sales and marketing efficiency [24][25] - **Sales Strategy**: The focus is on increasing utilization within existing accounts rather than acquiring new accounts, leveraging recent product iterations [20][26] Future Outlook - **Product Launches**: Anticipated launch of new technology in December, aimed at enhancing physician adoption without requiring a switch from existing microcatheters [17][30] - **Clinical Studies**: Ongoing clinical studies to support the efficacy of the technology across various applications, with plans for registry studies to gather robust data [27][29] - **Reimbursement Impact**: The introduction of mapping codes has resulted in a 30% increase in business, highlighting the importance of training hospitals for billing [31][32] Important but Overlooked Content - **Patient-Centric Approach**: The technology not only improves clinical outcomes but also reduces the need for long-term therapies, such as thyroid replacement, which can significantly enhance patient quality of life [12][15] - **Grassroots Adoption**: Many new applications have emerged from physician-led initiatives, indicating a strong grassroots demand for the technology [23][27] - **Cost Savings**: The technology has been shown to reduce overall procedure costs, providing additional financial incentives for hospitals [33]

Ligand Pharmaceuticals (NasdaqGM:LGND) FY Conference November 20, 2025 02:20 PM ET Company ParticipantsMelanie Herman - Executive Director of Investor Relations and FP&ATodd Davis - CEOConference Call ParticipantsNone - AnalystModeratorAll righty. Thank you, everyone, for being here. Up next is Ligand Pharmaceuticals, a company known for its diversified drug discovery technologies and its commitment to advancing innovation across the life science industries. Representing the company today is their Chief Exe ...

Summary of SM Energy Company FY Conference Call Company Overview - **Company**: SM Energy Company (NYSE: SM) - **Date of Conference**: November 20, 2025 - **Key Speakers**: Beth McDonald (COO), Wade Pursell (CFO), Pat Lytle (VP of Finance) Key Points Company Strategy and Culture - The company emphasizes a culture of **servant leadership** and high integrity, focusing on empowering teams and maintaining a strong talent pool [2][3] - SM Energy has a **117-year history** and has demonstrated resilience through various market dynamics, maintaining a strategy centered on **value creation** and innovative thinking [4] Recent Developments - SM Energy signed a **merger agreement** with Civitas Resources, which is seen as a **transformational** move for the company [5] - The merger is expected to generate **$200-$300 million** in synergies, translating to an estimated **$1 billion-$1.5 billion** in net present value (NPV), representing up to **30% of the current market cap** [5] Financial Performance - The company reported a strong **Q3 performance**, although overshadowed by the merger announcement [5] - Pro forma estimates suggest a combined free cash flow of approximately **$1.5 billion** for 2025 [8] Market Valuation - Current market valuation indicates an upside potential of **120%** for SM Energy compared to a mere **3%** for its peer group [7] - The market is perceived to be undervaluing the company's true potential and upside [7] Asset Management and Divestiture Plans - The company is evaluating its combined portfolio post-merger, focusing on **commodity mix** and asset quality to maximize free cash flow [10] - A **$1 billion divestiture target** has been set to streamline operations and enhance liquidity [34] Operational Efficiency - The company has implemented **AI and machine learning** in production operations, leading to improved efficiency and increased production [22][23] - Cost-saving measures have been identified, including optimizing chemical costs and transportation logistics [36] Political and Regulatory Environment - The management is familiar with the **Colorado political landscape** and has noted improvements in permitting times, which have decreased by **50%** over the past few years [12] Future Outlook - The company is optimistic about its ability to pivot towards gas production if market conditions are favorable, particularly if gas prices sustain above **$4** [25] - The integration of Civitas is expected to enhance operational capabilities and drive further efficiencies [14] Technical Developments - Encouraging results are anticipated from ongoing drilling in the **Barnett Woodford** area, with improvements in drilling times noted [37] - The company is exploring innovative completion designs and remote fracking techniques to enhance productivity and reduce costs [39][41] Transportation and Marketing - The company is actively looking to optimize its transportation strategies to improve margins, with ongoing expansions in infrastructure expected to benefit operations [49][50] Conclusion SM Energy is positioned for significant growth and operational efficiency through its merger with Civitas Resources, with a strong focus on value creation, innovative practices, and strategic asset management. The company is optimistic about its future prospects, leveraging technology and market opportunities to enhance shareholder value.

Summary of RenovoRx Conference Call (November 20, 2025) Company Overview - **Company**: RenovoRx (NasdaqCM:RNXT) - **Market Cap**: Approximately $30 million - **Focus**: Interventional oncology with a late-stage product in development and a commercial catheter device - **Current Stock Price**: Approximately $0.75 - **Analyst Rating**: Buy rating with a price target of $3 per share [1][17] Core Business and Product Development - **Product**: RenovoCath, a catheter device for localized chemotherapy - **Revenue**: Achieved $900,000 in revenue through Q3 2025 without a dedicated sales and marketing team [3][13] - **Market Potential**: Estimated peak sales potential for the catheter is about $400 million [3][8] - **Commercialization Strategy**: Initiated in early 2025, focusing on understanding market dynamics and barriers to adoption [3][9] Technology and Treatment Approach - **Innovative System**: Developed a new treatment method called TransArterial Microperfusion (TAMP) for localized chemotherapy [2][5] - **Mechanism of Action**: Allows for a hundred-fold increase in tissue concentration of chemotherapy compared to systemic delivery [7][8] - **Targeted Conditions**: Primarily focused on locally advanced pancreatic cancer, with ongoing phase III trials [4][10] Clinical Trials and Efficacy - **Phase III Trial**: Enrollment expected to complete early next year, with final data anticipated in 2027 [4][14] - **Survival Benefits**: Interim analysis shows a six-month survival benefit, with patients living approximately 21.5 months compared to 15.5 months in the control group [10][40] - **Quality of Life**: Notable 65% reduction in systemic toxicities and adverse events compared to traditional therapies [11][40] Market Dynamics and Sales Strategy - **Target Market**: Approximately 200 hospitals in the U.S. with specialized cancer centers [9] - **Sales Force**: Currently expanding with the hiring of a Senior Director of Sales and Marketing, along with additional sales representatives [9][20] - **Revenue Model**: Each patient may require multiple procedures, potentially generating $50,000 to $100,000 in revenue per patient [19][22] Financial Overview - **Cash Position**: $10 million in cash as of Q3 2025, with a monthly burn rate of $800,000 [16][44] - **Profitability Outlook**: Positive contribution margin on the device, with a goal to reach break-even with 25-50 hospitals actively using the device [22][23] Future Prospects and Strategic Initiatives - **Post-Marketing Registry Study**: Launched to track data on the use of RenovoCath across various cancers [12][13] - **Expansion Plans**: Exploring additional indications and potential partnerships with other biotech firms for drug-device combinations [42][43] - **Regulatory Strategy**: Aiming for a J-code drug reimbursement for the drug-device combination, which could significantly increase market potential [17] Key Takeaways - RenovoRx is positioned to disrupt traditional cancer treatment paradigms with its innovative localized chemotherapy approach - The company is on track to expand its market presence and revenue generation capabilities through strategic hiring and commercialization efforts - Clinical trial results and a strong focus on quality of life improvements are expected to drive adoption among oncologists and patients alike [10][11][40]

Financial Data and Key Metrics Changes - The company reported a total of 6,503,511 shares of common stock outstanding, with 5,736,174 shares present at the meeting, representing 88.20% of the total votes eligible to be cast [12] - The election results showed that Debbie H. Guthrie received 3,215,117 votes (60.67%), Kathy M. MacDougall received 3,217,063 votes (60.70%), and Matthew E. Webb received 3,216,572 votes (60.69%) [13] - The advisory vote on executive compensation received 2,796,098 votes in favor (52.75%) [14] Business Line Data and Key Metrics Changes - No specific data on business lines was provided in the meeting records Market Data and Key Metrics Changes - No specific market data was discussed in the meeting records Company Strategy and Development Direction and Industry Competition - The company appointed Deloitte & Touche, LLP as independent auditors for the fiscal year ending June 30, 2026, indicating a focus on maintaining strong governance and compliance [11] Management's Comments on Operating Environment and Future Outlook - Management did not provide specific comments on the operating environment or future outlook during the meeting Other Important Information - The meeting confirmed that a quorum was present, allowing for the election of directors and other business to proceed [16] - The results of the votes will be verified and disclosed in a Form 8-K filing with the Securities and Exchange Commission [15] Q&A Session Summary - No questions were raised during the Q&A session, and the meeting proceeded without any inquiries [12]